1. **Patient Information**
   1.1 Patient ID  
   1.2 Name  
   1.3 Date of Birth  
   1.4 Age  
   1.5 Gender  
   1.6 Contact Information (if applicable)  
   1.7 Address (if applicable)  

2. **Diagnosis Information**
   2.1 Diagnosis Center  
   2.2 Doctor's Name  
   2.3 Accession Number  
   2.4 Date of Diagnosis  
   2.5 Date of Report Issuance  
   2.6 CLIA Number  
   2.7 Laboratory Medical Director  
   2.8 Method of Analysis (e.g., NGS, Immunochemistry, etc.)  
   2.9 Pipeline Version (Report Version)  

3. **Cancer Information**
   3.1 Cancer Type  
   3.2 Cancer Stage (if applicable)  
   3.3 Cancer Grade (if applicable)  
   3.4 Cancer Location in the Body  
   3.5 Tumor Specimen Source  
   3.6 Tumor Percentage in Sample  
   3.7 Normal Specimen Source (if applicable)  
   3.8 Date of Tumor Sample Collection  
   3.9 Date Tumor Sample Received  
   3.10 Date of Normal Sample Collection (if applicable)  
   3.11 Date Normal Sample Received (if applicable)  

4. **Biomarkers**
   4.1 **General Biomarkers**
       4.1.1 Microsatellite Instability (MSI)  
       4.1.2 Tumor Mutational Burden (TMB)  
       4.1.3 Tumor Mutational Burden Percentile (if applicable)
       4.1.4 Loss of Heterozygosity (LOH) (if applicable)  
       4.1.5 Mismatch Repair (MMR) Status  
       4.1.6 PDL1 Expression (if applicable)  
       4.1.7 EBV (Epstein-Barr Virus) Status (if applicable)  
       4.1.8 Other Immunotherapy Markers (if applicable)  
       4.1.9 List of Low-Coverage Regions (Indeterminate Genes)  
       
   4.2 **Gene Mutations**  
   For each mutation:
       4.2.1 Gene Name  
       4.2.2 DNA Mutation Description (e.g., c.20G>T)  
       4.2.3 Protein Variant (e.g., p.P252R)  
       4.2.4 Somatic or Germline  
       4.2.5 Potentially Actionable or Biologically Relevant  
       4.2.6 Variant Allele Fraction (VAF)  
       4.2.7 Mutation Type (e.g., missense, nonsense, frameshift, etc.)  
       4.2.8 Transcript ID  
       4.2.9 Exon Number  
       4.2.10 Functional Impact (e.g., Loss of Function, Gain of Function)  
       4.2.11 Analyte  
       4.2.12 Method of Detection  
       4.2.13 Pathogenicity (e.g., pathogenic, likely pathogenic, uncertain significance)  
       4.2.14 Pertinent Negative Results (if applicable)  

   4.3 **Immunochemistry Biomarkers**  
   For each biomarker:
       4.3.1 Biomarker Name (e.g., PDL1, HER2, etc.)  
       4.3.2 Number of Stained Cells  
       4.3.3 Percentage of Expression  
       4.3.4 Interpretation (Positive/Negative)  

5. **Therapeutic Information**
   5.1 **FDA-Approved Therapies for Current Diagnosis**  
   For each therapy:
       5.1.1 Therapy Name  
       5.1.2 Therapy Type (e.g., Chemotherapy, Immunotherapy, Targeted Therapy)
       5.1.3 Medication  
       5.1.4 Evidence Source (e.g., NCCN, MSK-OncoKB, etc.)  
       5.1.5 **Associated Biomarkers**  
           5.1.5.1 Biomarker Name 
           5.1.5.2 Biomarker level (if applicable) 
           5.1.5.3 Positively/Negatively Associated (Benefit/Lack of Benefit)  

   5.2 **FDA-Approved Therapies for Other Indications**  
   For each therapy:
       5.2.1 Therapy Name  
       5.2.2 Therapy Type
       5.2.3 Medication  
       5.2.4 Evidence Source  
       5.2.5 **Associated Biomarkers**  
           5.2.5.1 Biomarker Name  
           5.2.5.2 Positively/Negatively Associated  

6. **Clinical Trials**
   For each trial:
       6.1 Trial Title  
       6.2 Clinical Trial ID  
       6.3 Phase of Trial (e.g., Phase 1, Phase 2)  
       6.4 Trial Location (if available)  
       6.5 Therapy Type (chemo or targeted)
       6.6 Medication
       6.7 **Associated Mutations**  
           6.5.1 List of Mutations Associated with the Trial  

7. **Variants of Unknown Significance (VUS)**
   For each variant:
       7.1 Gene Name
       7.2 DNA Alteration
       7.3 Protien Variant
       7.4 Mutation Type  
       7.5 Variant Allele Fraction (VAF)  
       7.6 Transcript ID  
       7.7 Exon Number  
       7.8 Functional Impact (if known)  
       7.9 Somatic or Germline

8. **Additional Indicators**
   8.1 Prognostic Markers (e.g., KRAS mutation with unfavorable prognosis)  
   8.2 Other Molecular Markers  
   8.3 Special Notes on Cancer Progression or Drug Resistance (if applicable)
